Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

Sector

Pharmaceuticals

Calendar

08-04 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
31/07/26	€48.17	-0.33%
30/07/26	€48.33	+1.62%
29/07/26	€47.56	+0.59%
28/07/26	€47.28	-0.19%
27/07/26	€47.37	+2.67%

Real-time CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

More quotes

Analysis / Opinion

Bayer: Inching closer to being unshackled

June 30, 2026 at 08:37 pm

Can Bayer Still Recover?

May 21, 2026 at 11:06 am

Roundup: Bayer ordered to pay $2.1bn to an American suffering from cancer

March 24, 2025 at 01:21 pm

More analyses

Market Closed - CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL) Other stock markets 18:30:00 31/07/2026 +03			5-day change	1st Jan Change
48.17 ^EUR	-0.33%		+2.48%	-33.31%

07-31	DAX records in sight, markets remain prone to volatility	RE
07-31	Corteva raises full-year profit forecast, shares fall after revenue miss	RE

Market Cap	47.21B 54.3B 43.94B 40.34B 76.18B 5,184B 77.36B 518B 203B 2,581B 204B 199B 8,654B	P/E 2026 *	20.8x	P/E 2027 *	15.5x
Enterprise Value	79.05B 90.93B 73.58B 67.55B 128B 8,680B 130B 867B 340B 4,321B 342B 334B 14,491B	EV / Sales 2026 *	1.73x	EV / Sales 2027 *	1.62x
Free-Float	100%	Yield 2026 *	0.47%	Yield 2027 *	1.31%

07-31	DAX records in sight, markets remain prone to volatility	RE
07-31	Corteva raises full-year profit forecast, shares fall after revenue miss	RE
07-30	Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US	RE
07-30	Bayer Seeks Chinese Approval for Kerendia in Non-diabetic Chronic Kidney Disease	MT
07-28	One A Day Introduces New Women's Multi Gummy Formula With 1,000 Mcg Biotin	CI
07-27	DKSH to Purchase Oral Contraceptive Brand Meliane	MT
07-27	DKSH Holding AG agreed to acquire Meliane oral contraceptive brand from Bayer Aktiengesellschaft.	CI
07-24	AlphaValue/Baader Europe Upgrades Bayer to Add, Trims PT	MT
07-24	Accord Healthcare's Hypertension Drug Wins European Medicines Agency's Positive Opinion	MT
07-23	Bayer Aktiengesellschaft Calls for Redemption of the Senior Unsecured Fixed Rate Notes Due 2026	CI
07-22	Kairos Pharma Collaborates With Bayer to Assess Prostate Cancer Treatment Combination	MT
07-17	Bayer Ag and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials	CI
07-17	BAYER AG : JP Morgan keeps its Buy rating	ZD

07-24	AlphaValue/Baader Europe Upgrades Bayer to Add, Trims PT	MT
07-17	BAYER AG : JP Morgan keeps its Buy rating	ZD
07-14	Where would AI lead Pharma in the long run?
07-14	BAYER AG : Gets a Buy rating from Barclays	ZD
07-13	BAYER AG : UBS keeps its Buy rating	ZD

Bayer AG Stock CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

Stocks

BAYNd

DE000BAY0017

Pharmaceuticals

Valuation: Bayer AG

Chart: Bayer AG

Latest news : Bayer AG

Last Transcript: Bayer AG

Analysts' recommendations: Bayer AG

Press Releases: Bayer AG

News in other languages: Bayer AG

Quotes and Performance

Course Extremes

Managers and Directors: Bayer AG

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

07-30	Bayer : submits application for next indication of Kerendia in China	PU
07-28	One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin	BU
07-23	New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters	BU
07-23	Bayer : New Economist Enterprise research highlights why integrating self-care into health systems matters	PU
07-17	Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials	BU

07-31	Dax-Rekorde in Sicht - Börsen bleiben schwankungsanfällig
07-31	Agenda Zonebourse des résultats de sociétés : semaine du 3 au 7 août 2026
07-31	Agenda FRANCE & INTERNATIONAL - Semaine du 3 août
07-31	19 TERMINE, die in der Woche wichtig werden -2- (Donnerstag/Freitag)
07-31	19 TERMINE, die in der Woche wichtig werden -1- (Montag - Mittwoch)

1 week	+4.40%
Current month	+0.12%
1 month	+0.12%
3 months	+26.96%
6 months	+8.48%
Current year	+30.21%

Manager	Title	Age	Since
William Anderson CEO	Chief Executive Officer	60	01/06/2023
Judith Hartmann DFI	Director of Finance/CFO	57	01/06/2026
Philipp Blank CMP	Compliance Officer	-	-

Director	Title	Age	Since
André van Broich BRD	Director/Board Member	56	01/04/2012
Heike Hausfeld BRD	Director/Board Member	60	01/04/2017
Norbert Winkeljohann CHM	Chairman	68	28/04/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAYER AG	-0.33%	+2.48%	+76.35%	-9.37%	54.79B
ELI LILLY AND COMPANY	-0.53%	-3.95%	+55.23%	+152.74%	1,030B
JOHNSON & JOHNSON	+0.21%	-2.68%	+55.61%	+53.02%	617B
ABBVIE INC.	-2.51%	-3.25%	+32.76%	+67.76%	455B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	350B
NOVARTIS AG	-0.14%	-0.24%	+34.41%	+39.01%	299B
ASTRAZENECA PLC	-0.69%	-0.30%	+11.55%	+12.93%	265B
NOVO NORDISK A/S	-7.37%	-4.40%	-2.54%	-43.87%	225B
AMGEN INC.	-0.64%	+2.43%	+30.52%	+64.49%	209B
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.96%	+71.01%	163B
Average	-1.38%	+1.38%	+34.74%	+43.84%	401.41B
Weighted average by Cap.	-1.02%	-0.11%	+39.57%	+71.25%

	2026 *	2027 *
Net sales	45.6B 52.46B 42.45B 38.97B 73.6B 5,008B 74.74B 500B 196B 2,493B 197B 193B 8,360B	46.76B 53.79B 43.52B 39.96B 75.46B 5,134B 76.62B 513B 201B 2,556B 202B 198B 8,571B
Net income	2.13B 2.45B 1.98B 1.82B 3.43B 233B 3.48B 23.33B 9.16B 116B 9.19B 8.98B 390B	2.93B 3.37B 2.73B 2.51B 4.73B 322B 4.81B 32.17B 12.63B 160B 12.67B 12.39B 538B
Net Debt	31.84B 36.63B 29.64B 27.21B 51.39B 3,497B 52.18B 349B 137B 1,741B 138B 135B 5,837B	28.71B 33.03B 26.72B 24.54B 46.34B 3,153B 47.05B 315B 124B 1,570B 124B 121B 5,263B

1 week	45	48.71
1 month	45	53.9
3 years	18.39	53.9
5 years	18.39	67.99